Gary E Landreth

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6610642/gary-e-landreth-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89 papers	16,301 citations	49 h-index	97 g-index
97 ext. papers	18,673 ext. citations	8.5 avg, IF	6.38 L-index

#	Paper	IF	Citations
89	PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease.. *Genome Medicine*, **2022**, 14, 17	14.4	2
88	The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease.. *Science Translational Medicine*, **2022**, 14, eabl7634	17.5	3
87	INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia. *Neurobiology of Disease*, **2021**, 153, 105303	7.5	16
86	Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer's Disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 2, e058740	1.2	0
85	The role of microglia niacin receptor (HCAR2) in Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e052716	1.2	
84	PLCG2 expression is associated with plaque-associated microglia in Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e054755	1.2	
83	Therapeutic potential of niacin in Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e040679	1.2	1
82	Three-dimensional nanoscopy of whole cells and tissues with in situ point spread function retrieval. *Nature Methods*, **2020**, 17, 531-540	21.6	32
81	Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. *Neurobiology of Disease*, **2020**, 142, 104956	7.5	28
80	The effect of amyloid on microglia-neuron interactions before plaque onset occurs independently of TREM2 in a mouse model of Alzheimer's disease. *Neurobiology of Disease*, **2020**, 145, 105072	7.5	5
79	Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. *Molecular Neurodegeneration*, **2020**, 15, 62	19	7
78	Plaque-associated myeloid cells derive from resident microglia in an Alzheimer's disease model. *Journal of Experimental Medicine*, **2020**, 217,	16.6	22
77	TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment. *Glia*, **2019**, 67, 1873-1892	9	28
76	Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation. *Annual Review of Pharmacology and Toxicology*, **2019**, 59, 237-261	17.9	20
75	PPAR/ agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1 9 astrocytes. *Glia*, **2019**, 67, 146-159	9	21
74	Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease. *Journal of Neuroinflammation*, **2018**, 15, 43	10.1	12
73	Pharmacological Inhibition of ERK Signaling Rescues Pathophysiology and Behavioral Phenotype Associated with 16p11.2 Chromosomal Deletion in Mice. *Journal of Neuroscience*, **2018**, 38, 6640-6652	6.6	39

72	Active PSF shaping and adaptive optics enable volumetric localization microscopy through brain sections. *Nature Methods*, **2018**, 15, 583-586	21.6	39
71	The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease. *Molecular Neurodegeneration*, **2018**, 13, 29	19	95
70	ERK/MAPK signaling and autism spectrum disorders. *Progress in Brain Research*, **2018**, 241, 63-112	2.9	35
69	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. *Journal of Lipid Research*, **2017**, 58, 1937-1949	6.3	43
68	Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?. *Neuroscience and Biobehavioral Reviews*, **2017**, 77, 148-164	9	80
67	Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*, **2017**, 37, 637-647	6.6	225
66	TREM2 in Neurodegenerative Diseases. *Molecular Neurodegeneration*, **2017**, 12, 56	19	176
65	Chronic impairment of ERK signaling in glutamatergic neurons of the forebrain does not affect spatial memory retention and LTP in the same manner as acute blockade of the ERK pathway. *Hippocampus*, **2017**, 27, 1239-1249	3.5	6
64	Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. *Neuropharmacology*, **2017**, 123, 465-476	5.5	53
63	ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. *Journal of NeuroImmune Pharmacology*, **2016**, 11, 61-72	6.9	36
62	Retinoids and motor neuron disease: Potential role in amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, **2016**, 360, 115-20	3.2	17
61	A Extraction from Murine Brain Homogenates. *Bio-protocol*, **2016**, 6,	0.9	16
60	Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy. *Scientific Reports*, **2016**, 6, 33176	4.9	21
59	02-07-06: The R47H Trem2 Variant Modifies Alzheimer's Disease Pathology and Neuroinflammation in a Novel Knock-In Mouse Model **2016**, 12, P243-P243		
58	P3-012: Advancing Therapeutics for Neuroinflammation in Alzheimer's Disease: Clinical Development Considerations **2016**, 12, P822-P822		
57	A randomized controlled study to evaluate the effect of bexarotene on amyloid- and apolipoprotein E metabolism in healthy subjects. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2016**, 2, 110-120	6	37
56	Targeting innate immunity for neurodegenerative disorders of the central nervous system. *Journal of Neurochemistry*, **2016**, 138, 653-93	6	87
55	Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions. *Molecular and Cellular Biology*, **2015**, 35, 1238-53	4.8	19

54	TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *Journal of Experimental Medicine*, **2015**, 212, 287-95	16.6	407
53	ERK2 Alone Drives Inflammatory Pain But Cooperates with ERK1 in Sensory Neuron Survival. *Journal of Neuroscience*, **2015**, 35, 9491-507	6.6	27
52	Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. *Journal of Neuroscience*, **2015**, 35, 9173-81	6.6	38
51	Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. *Journal of Neuroscience*, **2015**, 35, 6532-43	6.6	104
50	Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation. *Journal of Neuroinflammation*, **2015**, 12, 7	10.1	48
49	Dentate Gyrus Development Requires ERK Activity to Maintain Progenitor Population and MAPK Pathway Feedback Regulation. *Journal of Neuroscience*, **2015**, 35, 6836-48	6.6	20
48	Neuroinflammation in Alzheimer's disease. *Lancet Neurology, The*, **2015**, 14, 388-405	24.1	2760
47	Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor δ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. *Journal of Biological Chemistry*, **2015**, 290, 21591-602	5.4	58
46	Lipidated APOE has effects on cognitive function that are independent of amyloid-β pathology. *Brain*, **2015**, 138, 3470-2	11.2	
45	The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. *Journal of Neuroscience*, **2015**, 35, 3190-200	6.6	98
44	Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. *Journal of Neuroscience*, **2014**, 34, 12538-46	6.6	72
43	Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. *Neurobiology of Aging*, **2014**, 35, 2091-5	5.6	45
42	Nuclear receptors in neurodegenerative diseases. *Neurobiology of Disease*, **2014**, 72 Pt A, 104-16	7.5	67
41	In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. *Molecular Neurodegeneration*, **2013**, 8, 13	19	79
40	Evidence for impaired amyloid β clearance in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2013**, 5, 33	9	133
39	Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". *Science*, **2013**, 340, 924-g	33.3	59
38	Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. *Journal of Neuroscience*, **2012**, 32, 15112-23	6.6	55
37	Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. *Journal of Neuroscience*, **2012**, 32, 10117-28	6.6	278

36	ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. *Science*, **2012**, 335, 1503-6	33.3	776
35	Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes. *Journal of Neuroscience*, **2012**, 32, 8663-77	6.6	65
34	Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's disease β-amyloidosis mouse model. *Journal of Neuroscience*, **2011**, 31, 15962-71	6.6	96
33	Specific functions for ERK/MAPK signaling during PNS development. *Neuron*, **2011**, 69, 91-105	13.9	153
32	The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. *Journal of Neuroscience*, **2011**, 31, 843-50	6.6	127
31	A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. *Archives of Neurology*, **2011**, 68, 45-50		145
30	Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. *Dementia and Geriatric Cognitive Disorders*, **2010**, 30, 131-46	2.6	237
29	The role of microglia in amyloid clearance from the AD brain. *Journal of Neural Transmission*, **2010**, 117, 949-60	4.3	393
28	Inflammation, microglia, and Alzheimer's disease. *Neurobiology of Disease*, **2010**, 37, 503-9	7.5	350
27	Microglia and inflammation in Alzheimer's disease. *CNS and Neurological Disorders - Drug Targets*, **2010**, 9, 156-67	2.6	275
26	Microglia in central nervous system diseases. *Journal of NeuroImmune Pharmacology*, **2009**, 4, 369-70	6.9	11
25	MAPSing CNS development and cognition: an ERKsome process. *Neuron*, **2009**, 61, 160-7	13.9	145
24	ApoE promotes the proteolytic degradation of Abeta. *Neuron*, **2008**, 58, 681-93	13.9	680
23	The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. *CNS Drugs*, **2008**, 22, 1-14	6.7	121
22	Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. *Journal of Neuroscience*, **2008**, 28, 6983-95	6.6	205
21	Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17115-20	11.5	134
20	PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. *Neurotherapeutics*, **2008**, 5, 481-9	6.4	229
19	Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. *Current Alzheimer Research*, **2007**, 4, 159-64	3	87

18	Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 10601-6	11.5	262
17	PPARs in the brain. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2007**, 1771, 1031-45	5	230
16	Neural-specific deletion of ERK2 results in frontal cortical neuropil thread formation and astrogliosis. *FASEB Journal*, **2007**, 21, A24	0.9	
15	Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. *Journal of Biological Chemistry*, **2006**, 281, 20842-20850	5.4	106
14	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 443-8	11.5	332
13	PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. *Experimental Neurology*, **2006**, 199, 245-8	5.7	49
12	ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. *Journal of Immunology*, **2005**, 175, 2374-80	5.3	66
11	The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. *Journal of Neuroscience*, **2005**, 25, 7805-12	6.6	175
10	Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. *Brain*, **2005**, 128, 1442-53	11.2	455
9	Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. *Journal of Neuroscience*, **2004**, 24, 9838-46	6.6	331
8	Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. *Journal of Neuroinflammation*, **2004**, 1, 11	10.1	36
7	A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. *Learning and Memory*, **2003**, 10, 26-39	2.8	128
6	Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. *Journal of Neuroscience*, **2003**, 23, 7504-9	6.6	424
5	Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. *Microscopy Research and Technique*, **2001**, 54, 59-70	2.8	58
4	Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. *Annals of Neurology*, **2001**, 49, 276	9.4	48
3	Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. *Journal of Biological Chemistry*, **2001**, 276, 18169-77	5.4	293
2	Inflammation and Alzheimer's disease. *Neurobiology of Aging*, **2000**, 21, 383-421	5.6	3490
1	Physiological stress and nerve growth factor treatment regulate stress-activated protein kinase activity in PC12 cells. *Journal of Neurobiology*, **1998**, 36, 537-49		7